Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer

Figures & data

Figure 1 Enzyme digestion results of rs5745652 and rs2074725 sites of the HGF gene.

Notes: (A) Enzyme digestion results of the rs5745652 site; (B) enzyme digestion results of the rs2074725 site.
Abbreviation: HGF, hepatocyte growth factor.

Table 1 Distribution of genotype and allele frequencies of two HGF gene polymorphisms in the case and control groups

SNPs	Control group (n=80)	Case group (n=109)	P-value	OR (95% CI)
rs5745652
TT	2 (2.5)	21 (19.3)	Reference
CT	24 (30.0)	42 (38.5)	0.012	0.167 (0.036–0.777)
CC	54 (67.5)	46 (42.2)	<0.001	0.081 (0.018–0.365)
T	28 (17.5)	84 (38.5)	Reference
C	132 (82.5)	134 (61.5)	<0.001	0.338 (0.207–0.553)
rs2074725
CC	36 (45.0)	84 (77.1)	Reference
CA	34 (42.5)	22 (20.2)	0.001	0.277 (0.143–0.538)
AA	10 (12.5)	3 (2.8)	0.001	0.129 (0.033–0.495)
C	106 (66.3)	189 (86.7)	Reference
A	54 (33.7)	29 (13.3)	<0.001	0.301 (0.181–0.502)

Note: Data presented as n (%).

Abbreviations: CI, confidence interval; HGF, hepatocyte growth factor; SNPs, single nucleotide polymorphisms; OR, odds ratio.

Table 2 Serum HGF protein level changes of each HGF genotypes before and after treatment between the case and control groups

SNP	Cases	HGF (pg/mL)
		Before	After
rs5745652
CT+TT	63	1,422.16±137.17	1,115.92±67.07a
CC	46	1,425.07±159.65	1,002.87±113.91a,b
rs2074725
CC	84	1,435.37±142.25	1,109.19±75.09a
CA+AA	25	1,383.10±155.67	930.52±70.60a,c

Notes:

a Compared with before treatment, P<0.05,

b compared with rs574565 CT+TT genotype, P<0.05,

c compared with rs2074725 CC genotype, P<0.05.

Abbreviations: HGF, hepatocyte growth factor; SNP, single nucleotide polymorphism.

Table 3 Comparisons of TACE curative effect of each HGF genotypes between the case and control groups

SNP	Cases	Effective	Ineffective	Total efficacy rate (%)	P-value
rs5745652					0.012
CT+TT	63	26	37	41.27
CC	46	36	10	78.26
rs2074725					0.008
CC	84	42	42	50.00
CA+AA	25	20	5	80.00

Abbreviations: HGF, hepatocyte growth factor; SNP, single nucleotide polymorphism; TACE, transcatheter arterial chemoembolization.

Table 4 Comparisons of survival quality of each HGF genotypes between the case and control groups

SNPs	Case	Before	After	3-month follow-up
rs5745652
CT+TT	63	59.88±13.33	59.35±9.66	69.57±10.47a
CC	46	63.38±10.88	63.39±10.28	76.28±9.33a,b
rs2074725
CC	84	60.85±13.17	60.27±9.99	70.67±10.52a
CA+AA	25	63.07±9.53	63.71±10.11	78.19±8.27a,c

Notes:

a Compared with before treatment, P<0.05,

b compared with rs574565 CT+TT genotype, P<0.05,

c compared with rs2074725 CC genotype, P<0.05. Data presented as mean ± standard deviation.

Abbreviations: SNPs, single nucleotide polymorphisms; HGF, hepatocyte growth factor.

Figure 2 Kaplan–Meier survival functions.

Notes: (A) Survival functions of each rs5745652 genotype; (B) survival functions of each rs2074725 genotype.

Table 5 Cox regression analysis of prognostic factors of PLA TACE therapy

Factor	B	SE	Wald	P-value	OR (95% CI)
rs5745652 site	−0.592	0.268	4.894	0.027	0.553 (0.327–0.935)
rs2074725 site	−0.827	0.289	8.181	0.004	0.438 (0.248–0.771)
BCLC stage	1.206	0.339	12.638	<0.001	3.339 (1.718–6.492)
Tumor size	0.719	0.310	5.387	0.020	2.052 (1.118–3.767)
TACE frequency	−0.367	0.298	1.521	0.217	0.693 (0.386–1.242)
Gender	0.553	0.365	2.286	0.131	1.738 (0.849–3.557)
Age	0.005	0.021	0.050	0.823	1.005 (0.964–1.048)

Abbreviations: CI, confidence interval; BCLC, Barcelona Clinic Liver Cancer; OR, odds ratio; PLA, primary liver cancer; SE, standard error; TACE, transcatheter arterial chemoembolization.